Clinical Trials Logo

Coronavirus Infections clinical trials

View clinical trials related to Coronavirus Infections.

Filter by:

NCT ID: NCT04397692 Terminated - COVID-19 Clinical Trials

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

Start date: June 13, 2020
Phase: N/A
Study type: Interventional

The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

NCT ID: NCT04397588 Recruiting - Clinical trials for ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2

Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19

ECMO-SARS
Start date: April 21, 2020
Phase:
Study type: Observational

The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.

NCT ID: NCT04397172 Terminated - COVID Clinical Trials

Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19

Start date: April 9, 2020
Phase:
Study type: Observational

COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization, sedation and mechanical ventilation, leaving them at a very high risk for developing Critical illness myopathy (CIM). CIM is associated with increased mortality and significant consequences for recovery and the ability to return to normal daily life. Up to date, there are no studies investigating the mid- or long-term course of the novel COVID-19 disease. The present study therefore aims to evaluate the clinical outcome of patients with ARDS due to SARS-CoV-2 with special attention to the development of CIM and its underlying causes. To provide the possibility of early diagnosis of CIM, critically ill patients will be regularly screened for muscle membrane alterations using (Muscle velocity recovery cycles) MRVC measurements. The primary endpoint is the incidence of CIM in patients with ARDS due to SARS-CoV-2, diagnosed according to the current diagnostic criteria.

NCT ID: NCT04396353 Completed - COVID-19 Clinical Trials

EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19

WHO
Start date: June 4, 2020
Phase:
Study type: Observational

The present study aims to assess the impact of exercise training, physical activity, and sedentary lifestyle on clinical outcomes in surviving patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therefore, this study will evaluate cross-sectionally and through a questionnaire in Portuguese and English on the internet, whether physically active patients have better outcomes for the disease such as shorter hospital stay, lesser symptoms, lesser need for mechanical ventilation, and medications.

NCT ID: NCT04395742 Not yet recruiting - Clinical trials for Coronavirus Disease 2019

1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study

TMX COVID
Start date: May 2020
Phase:
Study type: Observational

This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX). Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology. The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".

NCT ID: NCT04395716 Withdrawn - Covid-19 Clinical Trials

A Study of ResCureā„¢ to Treat COVID-19 Infection

Start date: January 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label interventional study which will test the efficacy of ResCureā„¢ in the treatment of patients with COVID-19 infection.

NCT ID: NCT04395170 Not yet recruiting - Clinical trials for Coronavirus Disease 2019 (COVID-19)

Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.

Start date: September 2020
Phase: Phase 2/Phase 3
Study type: Interventional

A randomized, open-label, multicenter, three-arm clinical trial to study the efficacy and safety of passive immunotherapy (convalescent plasma and anti-COVID-19 human immunoglobulin) compared to the standard treatment in Colombia.

NCT ID: NCT04395144 Completed - Respiratory Failure Clinical Trials

COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss

COVAYDE
Start date: May 15, 2020
Phase: N/A
Study type: Interventional

Prone positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ARDS) patients, with demonstrated reductions in mortality. Preliminary data suggest that awake proning in patients with COVID-19 treated with high-flow nasal oxygenation (HFNO) improves gas exchanges, and might be associated with a reduced need of mechanical ventilation, and reduced mortality. Further investigation in a formal randomized-controlled trial is need.

NCT ID: NCT04394377 Completed - Clinical trials for Coronavirus Infection

Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial

ACTION
Start date: June 21, 2020
Phase: Phase 4
Study type: Interventional

Pragmatic randomized clinical trial of patients admitted to the hospital with confirmed COVID-19 infection and elevated D-Dimer. Randomization 1:1 - Group 1 will undergo a routine full anticoagulation (oral or parenteral when needed) strategy; and group 2 will receive usual standard of care with prophylactic anticoagulation

NCT ID: NCT04394195 Completed - Clinical trials for CORONAVIRUS INFECTIONS

sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?

COVIDsFlt1
Start date: April 3, 2020
Phase:
Study type: Observational

Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.